Silviu Itescu – Managing Director & CEO – Mesoblast Limited (ASX:MSB) is developing innovative allogeneic cellular medicines to treat complex inflammatory diseases. The company’s portfolio of Phase 3 product candidates includes therapies for acute graft versus host disease, chronic heart failure and chronic low back pain.